Abbott Laboratories (ABT)vsDexCom Inc (DXCM)
ABT
Abbott Laboratories
$107.81
-0.14%
HEALTHCARE · Cap: $182.49B
DXCM
DexCom Inc
$84.75
+2.08%
HEALTHCARE · Cap: $31.49B
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 837% more annual revenue ($46.59B vs $4.97B). DXCM leads profitability with a 20.1% profit margin vs 11.7%. DXCM appears more attractively valued with a PEG of 1.56. DXCM earns a higher WallStSmart Score of 72/100 (B).
ABT
Buy52
out of 100
Grade: C-
DXCM
Strong Buy72
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-43.2%
Fair Value
$73.84
Current Price
$107.81
$33.97 premium
Intrinsic value data unavailable for DXCM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Every $100 of equity generates 31 in profit
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 24.3%
Earnings expanding 43.6% YoY
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Earnings declined 47.5%
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 12.2x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap. Revenue growth of 13.0% demonstrates continued momentum.
Bull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.
Bear Case : DXCM
The primary concerns for DXCM are PEG Ratio, P/E Ratio, Price/Book.
Key Dynamics to Monitor
ABT profiles as a value stock while DXCM is a mature play — different risk/reward profiles.
DXCM carries more volatility with a beta of 1.45 — expect wider price swings.
DXCM is growing revenue faster at 13.1% — sustainability is the question.
ABT generates stronger free cash flow (916M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (72/100 vs 52/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?